Abstract P2-09-15: NTRK fusions in breast cancer: Clinical, pathologic and genomic findings

Autor: JS Ross, J Chung, JE Elvin, J-A Vergilio, S Ramkissoon, J Suh, E Severson, S Daniel, GM Frampton, D Fabrizio, RJ Hartmaier, LA Albacker, SM Ali, AB Schrock, VA Miller, PJ Stephens, LM Gay

Publikováno v: Cancer Research. 78:P2-09

Background: The tropomysin receptor kinase A family includes the 3 NTRK1, NTRK2 and NTRK3 genes and plays major roles in neuronal development. The recent evidence of remarkable efficacy for kinase inhibitors (TKI) targeting NTRK across a wide variety

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b4b8073a0a60f01beaf32cf13a2c573e
https://doi.org/10.1158/1538-7445.sabcs17-p2-09-15

Abstract P1-05-07: Comprehensive genomic profiling of clinically malignant phyllodes tumors of the breast reveals frequent mutation of NF1 and other genes associated with PI3K and RAS pathway activation

Autor: LM Gay, JA Elvin, J-A Vergilio, J Suh, S Ramkissoon, S Ali, A Schrock, K Hirshfield, S Ganesan, VA Miller, PJ Stephens, JS Ross

Publikováno v: Cancer Research. 77:P1-05

Background: Malignant or metastatic breast phyllodes tumors (MPT) are exceptionally rare, and the underlying genomic drivers are still being elucidated. Recent studies report frequent mutations in the RAS and PI3K pathways but have not commonly repor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4e3861e73d01f05ebfbb2ef28b1638e7
https://doi.org/10.1158/1538-7445.sabcs16-p1-05-07

Abstract PD8-01: CDH1 mutated classic and pleomorphic invasive lobular breast carcinomas differ in genomic signatures and opportunities for targeted and immunotherapies

Autor: JS Ross, J Chung, JE Elvin, J-A Vergilio, S Ramkissoon, J Suh, E Severson, S Daniel, GM Frampton, D Fabrizio, RJ Hartmaier, LA Albacker, SM Ali, AB Schrock, VA Miller, PJ Stephens, LM Gay

Publikováno v: Cancer Research. 78:PD8-01

Background: Typically defined by negative IHC staining for E-cadherin, classic (CILC) and pleomorphic (PILC) are often combined as a single breast cancer subtype. We queried whether patients with relapsed metastatic disease, mCILC and mPILC, would ha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::02b3a044b20641eb707ff270a21ebb7f
https://doi.org/10.1158/1538-7445.sabcs17-pd8-01

Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.

Autor: Chung CH; Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida., Li J; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida., Steuer CE; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia., Bhateja P; Department of Internal Medicine and The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio., Johnson M; Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida., Masannat J; Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida., Poole MI; Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida., Song F; Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida., Hernandez-Prera JC; Department of Pathology, Moffitt Cancer Center, Tampa, Florida., Molina H; Department of Pathology, Moffitt Cancer Center, Tampa, Florida., Wenig BM; Department of Pathology, Moffitt Cancer Center, Tampa, Florida., Kumar S; Naveris Inc., Natick, Massachusetts., Kuperwasser C; Naveris Inc., Natick, Massachusetts., Stephens PJ; Naveris Inc., Natick, Massachusetts., Farinhas JM; Department of Radiology, Moffitt Cancer Center, Tampa, Florida., Shin DM; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia., Kish JA; Department of Personalized Medicine, Moffitt Cancer Center, Tampa, Florida., Muzaffar J; Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida., Kirtane K; Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida., Rocco JW; Department of Otolaryngology and The James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, Ohio., Schell MJ; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida., Saba NF; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia., Bonomi M; Department of Internal Medicine and The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Jun 01; Vol. 28 (11), pp. 2329-2338.

The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA.

Autor: Disel U; Acibadem University, Acibadem Hospital Medical Oncology, Adana, Turkey., Madison R; Foundation Medicine, Inc., Cambridge, Massachusetts, USA., Abhishek K; Bon Secours Cancer Institute, Richmond, Virginia, USA., Chung JH; Foundation Medicine, Inc., Cambridge, Massachusetts, USA., Trabucco SE; Foundation Medicine, Inc., Cambridge, Massachusetts, USA., Matos AO; Foundation Medicine, Inc., Cambridge, Massachusetts, USA., Frampton GM; Foundation Medicine, Inc., Cambridge, Massachusetts, USA., Albacker LA; Foundation Medicine, Inc., Cambridge, Massachusetts, USA., Reddy V; Foundation Medicine, Inc., Cambridge, Massachusetts, USA., Karadurmus N; Saglik Bilimleri Universities Gülhane Tıp Fakültesi, Ankara, Turkey., Benson A; Foundation Medicine, Inc., Cambridge, Massachusetts, USA., Webster J; Foundation Medicine, Inc., Cambridge, Massachusetts, USA., Paydas S; Department of Medical Oncology, Cukurova University School of Medicine, Adana, Turkey., Cabanillas R; Instituto de Medicina Oncológica y Molecular de Asturias, Asturias, Spain., Nangia C; Chao Family Comprehensive Cancer Center, University of California, Irvine School of Medicine, Orange, California, USA., Ozturk MA; Department of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Millis SZ; Foundation Medicine, Inc., Cambridge, Massachusetts, USA., Pal SK; City of Hope National Medical Center, Duarte, California, USA., Wilky B; University of Miami School of Medicine, Miami, Florida, USA., Sokol ES; Foundation Medicine, Inc., Cambridge, Massachusetts, USA., Gay LM; Foundation Medicine, Inc., Cambridge, Massachusetts, USA., Soman S; Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA., Ganesan S; Cancer Institute of New Jersey, New Brunswick, New Jersey, USA., Janeway K; Boston Children's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Stephens PJ; Foundation Medicine, Inc., Cambridge, Massachusetts, USA., Zhu VW; Chao Family Comprehensive Cancer Center, University of California, Irvine School of Medicine, Orange, California, USA., Ou SI; Chao Family Comprehensive Cancer Center, University of California, Irvine School of Medicine, Orange, California, USA., Lovly CM; Vanderbilt Medical Center, Nashville, Tennessee, USA., Gounder M; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Schrock AB; Foundation Medicine, Inc., Cambridge, Massachusetts, USA., Ross JS; Foundation Medicine, Inc., Cambridge, Massachusetts, USA.; SUNY Upstate Medical University, Syracuse, New York, USA., Miller VA; Foundation Medicine, Inc., Cambridge, Massachusetts, USA., Klempner SJ; The Angeles Clinic and Research Institute, Los Angeles, California, USA., Ali SM; Foundation Medicine, Inc., Cambridge, Massachusetts, USA.

Publikováno v: The oncologist [Oncologist] 2020 Jan; Vol. 25 (1), pp. e39-e47. Date of Electronic Publication: 2019 Oct 11.